Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TB

EU flag

Europe extends clinical trial project with African researchers

Partnership has already developed eight improved medical treatments

- PMLiVE

Otsuka wins approval for TB drug Deltyba

Second drug approved by EC in 2014 for multidrug resistant tuberculosis

- PMLiVE

Tuberculosis: treatment and prevention

One of the most significant global diseases, effective new TB therapies are sorely needed

EU flag

J&J gets EU green light for novel TB drug

Sirturo approved to treat multidrug resistant form of the disease

- PMLiVE

Cell wall inhibitors for bacterial infections

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Janssen’s Sirturo wins backing for conditional EU licence

CHMP recommends first-in-class multidrug-resistant tuberculosis treatment

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

- PMLiVE

Pfizer and Otsuka face drug rejections in Europe

EMA turns down Xeljanz for rheumatoid arthritis and delamanid for tuberculosis

- PMLiVE

Video for neglected tropical diseases challenges viewers

Non-profit organisation END7 asks: 'Can you watch what they watched?'

- PMLiVE

Pharma companies partner with Japanese government

GHIT Fund will support development of medicines for infectious diseases in developing countries

- PMLiVE

Otsuka files new TB candidate in Japan as shortages worsen

Delamanid shows promise in multi-drug resistant TB but supplies of rifampin are low

- PMLiVE

WHO claims $1.3bn annual funding gap for tuberculosis research

Says action needs to be taken now to halt spread of multi-drug resistant TB

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links